van Geel Albertus N, Wouters Michel W, van der Pol Carmen, Schmitz Paul I M, Lans Titia
Department of Surgical Oncology, Erasmus Medical Center/Daniel den Hoed Cancer Center, Rotterdam, The Netherlands.
Breast. 2009 Apr;18(2):94-9. doi: 10.1016/j.breast.2009.01.005. Epub 2009 Feb 24.
Evaluation of morbidity, mortality and oncologic outcome of patients treated with a chest wall resection for isolated breast cancer recurrences in the Internal Mammary Chain. Retrospectively we retrieved data from 29 patients. Multivariate analysis was performed to identify prognostic factors for (disease-free) survival. There were no postoperative deaths. Complications occurred in 11 patients. The median follow-up after CWR for all 16 patients still alive at the end of this study is 18.4 months. Nine patients were free of cancer. The 3-year overall and disease-free survival is 59.2% and 8.6%. The median survival is 40.7 months. After multivariate analysis for each of the four endpoints studied, only one prognostic factor remains significant for survival: systemic therapy before CRW (p=0.004). For local recurrence-free survival a first CRW recurrence (p<0.00001) and for disease-free survival radicality of the resection (p=0.008) are independent prognostic factors. Chest wall resection is a safe and effective treatment for isolated breast cancer recurrences in the IMC. Surgically treated patients have a fair survival and some of them are even cured.
评估接受胸骨旁淋巴结孤立性乳腺癌复发胸壁切除术患者的发病率、死亡率和肿瘤学结局。我们回顾性地收集了29例患者的数据。进行多变量分析以确定(无病)生存的预后因素。术后无死亡病例。11例患者出现并发症。在本研究结束时仍存活的所有16例患者中,胸壁切除术后的中位随访时间为18.4个月。9例患者无癌。3年总生存率和无病生存率分别为59.2%和8.6%。中位生存期为40.7个月。对所研究的四个终点中的每一个进行多变量分析后,仅一个预后因素对生存仍具有显著意义:胸壁切除术前的全身治疗(p=0.004)。对于无局部复发生存,首次胸壁切除复发(p<0.00001)以及对于无病生存,切除的彻底性(p=0.008)是独立的预后因素。胸壁切除术是治疗胸骨旁淋巴结孤立性乳腺癌复发的一种安全有效的方法。接受手术治疗的患者有一定的生存率,其中一些患者甚至可以治愈。